Education
About Us
Working with TipRanks
Follow Us
Immucell Corp. (ICCC)
NASDAQ:ICCC
ICCC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.34 - $7.60
Previous CloseN/A
Volume9.49K
Average Volume (3M)39.30K
Market Cap
$59.83M
Enterprise Value$34.76M
Total Cash (Recent Filing)$4.60B
Total Debt (Recent Filing)$6.01B
Price to Earnings (P/E)―
Beta-0.31
Next Earnings
Aug 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding9,037,397
10 Day Avg. Volume76,232
30 Day Avg. Volume39,298
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.56
Price to Sales (P/S)0.00
P/FCF Ratio-8.56
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit0.01
Enterprise Value/Ebitda-0.06
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Immucell News
PremiumCompany Announcements
ImmuCell Announces CEO Succession Planning Process
PremiumCompany Announcements
Immucell Elects Directors, Rejects Compensation Proposals
PremiumCompany Announcements
ImmuCell Reports Record Sales and Income GrowthOptions Prices
Currently, No data available
---
Ownership Overview
1.58%
Insiders
3.58% Mutual Funds
4.07% Other Institutional Investors
87.69% Public Companies and
Individual Investors
ICCC FAQ
What was Immucell Corp.’s price range in the past 12 months?
Immucell Corp. lowest stock price was $3.34 and its highest was $7.60 in the past 12 months.
What is Immucell Corp.’s market cap?
Immucell Corp.’s market cap is $59.83M.
When is Immucell Corp.’s upcoming earnings report date?
Immucell Corp.’s upcoming earnings report date is Aug 07, 2025 which is in 34 days.
How were Immucell Corp.’s earnings last quarter?
Immucell Corp. released its earnings results on May 14, 2025. The company reported $0.161 earnings per share for the quarter, beating the consensus estimate of N/A by $0.161.
Is Immucell Corp. overvalued?
According to Wall Street analysts Immucell Corp.’s price is currently Overvalued.
Does Immucell Corp. pay dividends?
Immucell Corp. does not currently pay dividends.
What is Immucell Corp.’s EPS estimate?
Immucell Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immucell Corp. have?
Immucell Corp. has 9,037,397 shares outstanding.
What happened to Immucell Corp.’s price movement after its last earnings report?
Immucell Corp. reported an EPS of $0.161 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 7.943%.
Which hedge fund is a major shareholder of Immucell Corp.?
Currently, no hedge funds are holding shares in ICCC
Immucell Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth $6.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.43%
12-Months-Change
Fundamentals
Return on Equity
-1.01%
Trailing 12-Months
Asset Growth
5.97%
Trailing 12-Months
Company Description
Immucell Corp.
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
ICCC Company Deck
ICCC Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong sales growth, improved gross margins, and significant adjusted EBITDA performance, driven by increased production capacity and product line expansion. However, challenges remain with FDA licensing for Re-Tain and managing backlog, alongside potential sales variability due to seasonality.Read More>Technical Analysis
Opus Genetics
―
Fortress Biotech
―
Modular Medical
―
Burning Rock Biotech
―
Repare Therapeutics
―